Novo Shares Tumble on Forecast for Steep Drop in Sales

Core Viewpoint - Novo Nordisk A/S anticipates a sales decline this year due to increased competition for its drugs Ozempic and Wegovy, alongside the impact of US government initiatives to reduce drug prices [1][3]. Sales Outlook - Sales at constant exchange rates are projected to decrease by 5% to 13%, contrasting with analysts' expectations of a 1.4% decline [1]. - The last annual sales drop for the company occurred in 2017, primarily due to a price war over insulin in the US [2]. Competitive Landscape - Novo Nordisk faces intensified competition, particularly from Eli Lilly & Co.'s Zepbound, which has gained market leadership in the US [2]. - The emergence of generic versions of Ozempic is expected in international markets later this year, further challenging sales [2]. Market Dynamics - Despite an anticipated expansion in the global GLP-1 market, factors such as lower realized pricing and the loss of exclusivity for semaglutide in several countries are expected to negatively impact revenues [3]. Investor Sentiment - The company is working to regain investor confidence following a significant decline in share value in 2025 [4]. - A new stock buyback program worth up to 15 billion Danish kroner (approximately $2.4 billion) has been announced to bolster investor sentiment [4].